Reactive oxygen species-mediated synergistic and preferential induction of cell death and reduction of clonogenic resistance in breast cancer cells by combined cisplatin and FK228

Cancer Letters

Volumn 381, Issue 1, 2016, Pages 124-132

  Pluchino, Lenora Ann ^a   Choudhary, Shambhunath ^a,b   Wang, Hwa Chain Robert ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

Breast cancer; Cisplatin; ERK pathway; FK228; Reactive oxygen species

Indexed keywords

CASPASE 3; CASPASE 7; CISPLATIN; DNA; ESTROGEN RECEPTOR; GLUTATHIONE; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; ROMIDEPSIN; ANTINEOPLASTIC AGENT; DEPSIPEPTIDE; HRAS PROTEIN, HUMAN; PROTEIN P21;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CONTROL; CANCER RESISTANCE; CELL DEATH; CELL SPECIFICITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA DAMAGE; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENTIATION; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MCF10A RAS CELL LINE; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; BREAST NEOPLASMS; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; IC50; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; TIME FACTOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DEATH; CELL SURVIVAL; CISPLATIN; DEPSIPEPTIDES; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MCF-7 CELLS; NADPH OXIDASE; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS P21(RAS); REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84982840921     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.07.036     Document Type: Article

References (49)

1. [1] American Cancer Society, Cancer facts & figures 2015. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/index, 2015 (accessed 17.09.15).
2. [2] Roché, H., Vahdat, L.T., Treatment of metastatic breast cancer: second line and beyond. Ann. Oncol 22 (2011), 1000–1010.
3. [3] Sledge, G.W., Mamounas, E.P., Hortobagyi, G.N., Burstein, H.J., Goodwin, P.J., Wolff, A.C., Past, present, and future challenges in breast cancer treatment. J. Clin. Oncol 32 (2014), 1979–1986.
4. [4] Tkaczuk, K.H., Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin. Ther 31 (2009), 2273–2289.
5. [5] Chung, C.T., Carlson, R.W., Goals and objectives in the management of metastatic breast cancer. Oncologist 8 (2003), 514–520.
6. [6] Blay, J.Y., Le Cesne, A., Alberti, L., Ray-Coquart, I., Targeted cancer therapies. Bull. Cancer 92 (2005), 13–16.
7. [7] Kirk, R., Targeted therapies: the toxic reality of new drugs. Nat. Rev. Clin. Oncol, 9, 2012, 488.
8. [8] Ellis, L.M., Hicklin, D.J., Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin. Cancer Res 15 (2009), 7471–7478.
9. [9] McLaughlin, S.K., Olsen, S.N., Dake, B., De Raedt, T., Lim, E., Bronson, R.T., et al. The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell 24 (2013), 365–378.
10. [10] Hand, P.H., Vilasi, V., Thor, A., Ohuchi, N., Schlom, J., Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas. J. Natl. Cancer Inst 79 (1987), 59–65.
11. [11] Decatris, M.P., Sundar, S., O'Byrne, K.J., Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat. Rev 30 (2004), 53–81.
12. [12] Rudin, C.M., Yang, Z., Schumaker, L.M., VanderWeele, D.J., Newkirk, K., Egorin, M.J., et al. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 63 (2003), 312–318.
13. [13] Shamseddine, A.I., Farhat, F.S., Platinum-based compounds for the treatment of metastatic breast cancer. Chemotherapy 57 (2011), 468–487.
14. [14] LaPensee, E.W., Schwemberger, S.J., LaPensee, C.R., Bahassi el, M., Afton, S.E., Ben-Jonathan, N., Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase. Carcinogenesis 30 (2009), 1298–1304.
15. [15] Ueda, H., Manda, T., Matsumoto, S., Mukumoto, S., Nishigaki, F., Kawamura, I., et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J. Antibiot. (Tokyo) 47 (1994), 315–323.
16. [16] Vigushin, D.M., FR⋅901228 Fujisawa/National Cancer Institute. Curr. Opin. Investig. Drugs 3 (2002), 1396–1402.
17. [17] Bertino, E.M., Otterson, G.A., Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin. Investig. Drugs 20 (2011), 1151–1158.
18. [18] Tan, J., Cang, S., Ma, Y., Petrillo, R.L., Liu, D., Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol, 3, 2010, 5.
19. [19] Choudhary, S., Rathore, K., Wang, H.C.R., FK228 and oncogenic H-Ras synergistically induce Mek1/2 and Nox-1 to generate reactive oxygen species for differential cell death. Anticancer Drugs 21 (2010), 831–840.
20. [20] Robertson, F.M., Chu, K., Boley, K.M., Ye, Z., Liu, H., Wright, M.C., et al. The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis. J. Exp. Ther. Oncol 10 (2013), 219–233.
21. [21] Choudhary, S., Wang, H.C.R., Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells. Mol. Cancer Ther 6 (2007), 1099–1111.
22. [22] Choudhary, S., Sood, S., Wang, H.C., Synergistic induction of cancer cell death and reduction of clonogenic resistance by cisplatin and FK228. Biochem. Biophys. Res. Commun 436 (2013), 325–330.
23. [23] Brown, J.M., Wouters, B.G., Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59 (1999), 1391–1399.
24. [24] Choudhary, S., Sood, S., Donnell, R.L., Wang, H.C., Intervention of human breast cell carcinogenesis chronically induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Carcinogenesis 33 (2012), 876–885.
25. 2 cooperatively activated the ERK pathway in selective induction of human urinary bladder cancer J82 cell death. Mol. Carcinog 50 (2011), 215–219.
26. [26] Choudhary, S., Rathore, K., Wang, H.C.R., Differential induction of reactive oxygen species through Erk1/2 and Nox-1 by FK228 for selective apoptosis of oncogenic H-Ras-expressing human urinary bladder cancer J82 cells. J. Cancer Res. Clin. Oncol 137 (2010), 471–480.
27. [27] Choudhary, S., Wang, H.C.R., Role of reactive oxygen species in proapoptotic ability of oncogenic H-Ras to increase human bladder cancer cell susceptibility to histone deacetylase inhibitor for caspase induction. J. Cancer Res. Clin. Oncol 135 (2009), 1601–1613.
28. [28] Choudhary, S., Wang, H.C.R., Pro-apoptotic activity of oncogenic H-Ras for histone deacetylase inhibitor to induce apoptosis of human cancer HT29 cells. J. Cancer Res. Clin. Oncol 133 (2007), 725–739.
29. [29] Olive, P.L., Banath, J.P., The comet assay: a method to measure DNA damage in individual cells. Nat. Protoc 1 (2006), 23–29.
30. [30] Collins, A.R., Duthie, S.J., Dobson, V.L., Direct enzymatic detection of endogenous oxidative base damage in human lymphocyte DNA. Carcinogenesis 14 (1993), 1733–1735.
31. [31] Chou, T.C., Talalay, P., Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul 22 (1984), 27–55.
32. [32] Wang, X., Martindale, J.L., Holbrook, N.J., Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem 275 (2000), 3935–3943.
33. [33] Kim, Y.K., Kim, H.J., Kwon, C.H., Kim, J.H., Woo, J.S., Jung, J.S., et al. Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells. J. Appl. Toxicol 25 (2005), 374–382.
34. [34] Kim, H.J., Lee, J.H., Kim, S.J., Oh, G.S., Moon, H.D., Kwon, K.B., et al. Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity. J. Neurosci 30 (2010), 3933–3946.
35. [35] Deneke, S.M., Thiol based antioxidant. Curr. Top. Cell. Regul 36 (2000), 151–180.
36. [36] Siddik, Z.H., Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003), 7265–7279.
37. [37] Godwin, A.K., Meister, A., O'Dwyer, P., Huang, C.S., Hamilton, T.C., Anderson, M.E., High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. U.S.A. 89 (1992), 3070–3074.
38. [38] Pompella, A., Corti, A., Paolicchi, A., Giommarelli, C., Zunino, F., Gamma-glutamyltransferase, redox regulation and cancer drug resistance. Curr. Opin. Pharmacol 7 (2007), 360–366.
39. [39] Holohan, C., Van Schaeybroeck, S., Longley, D.B., Johnston, P.G., Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13 (2013), 714–726.
40. [40] Wang, H., Zhoua, W., Zhenga, Z., Zhanga, P., Tua, B., He, Q., et al. The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage. DNA Repair (Amst) 11 (2012), 146–156.
41. [41] Robey, R.W., Chakraborty, A.R., Basseville, A., Luchenko, V., Bahr, J., Zahn, Z., et al. Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol. Pharm 8 (2011), 2021–2031.
42. [42] Wilson, A.J., Lalani, A.S., Wass, E., Saskowski, J., Khabele, D., Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer. Gynecol. Oncol 127 (2012), 579–586.
43. [43] Sasada, T., Iwata, S., Sato, N., Kitaoka, Y., Hirota, K., Nakamura, K., et al. Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. J. Clin. Invest 97 (1996), 2268–2276.
44. [44] Miyajima, A., Nakashima, J., Yoshioka, K., Tachibana, M., Tazaki, H., Murai, M., Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br. J. Cancer 76 (1997), 206–210.
45. [45] Lehár, J., Krueger, A.S., Avery, W., Heilbut, A.M., Johansen, L.M., Price, E.R., et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol 27 (2009), 659–666.
46. [46] Subik, K., Lee, J.F., Baxter, L., Strzepek, T., Costello, D., Crowley, P., et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl.) 4 (2010), 35–41.
47. [47] Saini, K.S., Loi, S., de Azambuja, E., Metzger-Filho, O., Saini, M.L., Ignatiadis, M., et al. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat. Rev 39 (2013), 935–946.
48. [48] McCubrey, J.A., Steelman, L.S., Chappell, W.H., Abrams, S.L., Wong, E.W., Chang, F., et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 1773 (2007), 1263–1284.
49. [49] Blagosklonny, M.V., Trostel, S., Kayastha, G., Demidenko, Z.N., Vassilev, L.T., Romanova, L.Y., et al. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res 65 (2005), 7386–7392.